Cardiovascular effects of ghrelin and growth hormone secretagogues

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 8, Issue 2, 2008, Pages 133-137

  Isgaard, Jörgen ^a   Barlind, Anna ^a   Johansson, Inger ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INHIBITOR; CAPROMORELIN; DESOCTANOYL GHRELIN; GHRELIN; GROWTH HORMONE; GROWTH HORMONE SECRETAGOGUE; HEXARELIN; UNCLASSIFIED DRUG; CARDIOTONIC AGENT;

ACUTE DRUG ADMINISTRATION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CACHEXIA; CARDIOVASCULAR EFFECT; CELL METABOLISM; CELL PROLIFERATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PACING; HEART PROTECTION; HORMONE ACTION; HUMAN; IN VITRO STUDY; INOTROPISM; NONHUMAN; SINGLE DRUG DOSE; VASODILATATION; ANIMAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; DISEASE MODEL; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY; REVIEW; SECRETION;

ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; GHRELIN; GROWTH HORMONE; HEART FAILURE; HUMANS;

EID: 48249144020     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152908784533676     Document Type: Article

References (34)

1. Bowers, C.Y.; Chang, J.; Momany, F.A.; Folkers, K. Effects of the enkephalins and enkephalin analogs on release of pituitary hormones in vitro. In Molecular Endocrinol, Ed I MacIntyne. Amsterdam: Elsevier/North Holland. Biochemical. Press. 1977, pp. 287-292
2. Howard, A.D.; Feighner, S.D.; Cully, D.F.; Arena, J.P.; Liberator, P.A.; Rosenblum, C.I.; Hamelin, M.; Hreniuk, D.L.; Palyha, O.C.; Anderson, J.; Paress, P.S.; Diaz, C.; Chou, M.; Liu, K.K.; McKee, K.K.; Pong, S.S.; Chaung, L.Y.; Elbrecht, A.; Dashkevicz M.; Heavens, R.; Rigby, M.; Sirinathsinghji, D.J.; Dean, D.C.; Melillo, D.G.; Patchett A.A.; Nargund, R.; Griffin, P.R.; DeMartino, J.A.; Gupta, S.K.; Schaeffer, J.M.; Smith, R.G.; Van der Ploeg, L.H A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996, 273, 974-977
3. Kojima, M.; Kangawa, K. Ghrelin: structure and function. Physiol. Rev., 2006, 85, 495-522
4. Kojima, M.; Hosoda, H.; Date, Y.; Nakazato, M.; Matsuo, H.; Kangawa, K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 1999, 402, 656-666
5. Bisi, G.; Podio, V.; Valetto, M.R.; Broglio, F.; Bertuccio, G.; Del Rio, G.; Arvat E.; Boghen M.F.; Deghenghi, R.; Muccioli, G.; Ong, H.; Ghigo, E. Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans. J. Endocrinol. Invest., 1999, 22, 266-272.
6. Bisi G.; Podio V.; Valetto MR.; Broglio, F.; Bertuccio, G.; Aimaretti, G.; Pelosi, E.; Del Rio, G.; Muccioli, G.; Ong, H.; Boghen, M.F.; Deghenghi, R.; Ghigo, E.. Cardiac effects of hexarelin in hypopituitary adults. Eur. J. Pharmacol., 1999, 381, 31-38.
7. Enomoto M.; Nagaya N.; Uematsu M.; Okumura, H.; Nakagawa, E.; Ono, F.; Hosoda, H.; Oya, H.; Kojima, M.; Kanmatsuse, K.; Kangawa, K. Cardiovascular and hormonal effects of subcutaneous administration of ghrelin, a novel growth hormone-releasing peptide, in healthy humans. Clin. Sci., 2003, 105, 431-435.
8. Strömer, H.; Cittadini, A.; Douglas, P.S.; Morgan, J.P. Exogenously administered growth hormone and insulin-like growth factor-I alter intracellular Ca2+ handling and enhance cardiac performance. In vitro evaluation in the isolated isovolumic buffer-perfused rat heart. Circ. Res., 1996, 79, 227-236.
9. Nagaya, N.; Kojima, M.; Uematsu, M.; Yamagishi, M.; Hosoda, H.; Oya H.; Hayashi, Y.; Kangawa K. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am. J. Physiol. Regul Integr. Comp. Physiol., 2001, 280, R1483-R1487.
10. Wiley, K.E.; Davenport, A.P. Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1. Br. J. Pharmacol., 2002, 136, pp1146-1152.
11. Shimizu, Y.; Nagaya, N.; Teranishi, Y.; Imazu, M.; Yamamoto, H.; Shokawa, T.; Kangawa, K.; Kohno, N.; Yoshizumi, M. Ghrelin improves endothelial dysfunction through growth hormone-independent mechanisms in rats. Biochem. Biophys. Res. Commun. 2003, 310, 830-835.
12. Okumura, H.; Nagaya, N.; Enomoto, M.; Nakagawa, E.; Oya, H.; Kangawa, K. Vasodilatory effect of ghrelin, an endogenous peptide from the stomach. J. Cardiovasc. Pharmacol., 2002, 39, 779-783.
13. Lin, Y.; Matsumura, K.; Fukuhara, M.; Kagiyama, S.; Fujii, K.; Iida, M. Ghrelin acts at the nucleus of the solitary tract to decrease arterial pressure in rats. Hypertension, 2004, 43, 977-982.
14. Matsumura, K.; Tsuchihashi, T.; Fujii, K.; Abe, I.; Lida, M. Central ghrelin modulates sympathetic activity in concious rabbits. Hypertension, 2002, 40, 694-699
15. Li, W.G.; Gavrila, D.; Liu, X.; Wang, L.; Gunnlaugsson, S.; Stoll, L.L.; McCormick, M.L.; Sigmund, C.D.; Tang, C.; Weintraub, N.L. Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation, 2004, 109, 2221-2226.
16. Dixit, V.D.; Schaffer, E.M.; Pyle, R.S.; Collins, G.D.; Sakthivel, S.K.; Palaniappan, R.; Lillard, J.W. Jr.; Taub, D.D. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J. Clin. Invest., 2004, 114, 57-66
17. De Gennaro Colonna, V.; Rossoni, G.; Bernareggi, M.; Muller, E.E.; Berti F. Cardiac ischemia and impairment of vascular endothelium function in hearts from growth hormone-deficient rats: protection by hexarelin. Eur. J. Pharmacol., 1997, 334, 201-207.
18. Locatelli, V.; Rossoni, G.; Schweiger, F.; Torsello, A.; De Gennaro Colonna, V.; Bernareggi, M.; Deghenghi, R.; Muller, E.E.; Berti, F. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology, 1999, 140, 4024-4031.
19. Weekers, F.; Van Herck, E.; Isgaard, J.; Van den Berghe, G. Pretreatment with growth hormone-releasing peptide-2 directly protects against the diastolic dysfunction of myocardial stunning in an isolated, blood-perfused rabbit heart model. Endocrinology, 2000, 141, 3993-3999.
20. Tivesten, A.; Bollano, E.; Caidahl, K.; Kujacic, V.; Sun, X.Y.; Hedner, T.; Hjalmarson, A.; Bengtsson, B.A.; Isgaard, J. The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. Endocrinology, 2000, 141, 60-66.
21. King, M.K.; Gay, D.M.; Pan, L.C.; McElmurray, J.H..; 3rd, Hendrick, J.W.; Pirie, C.; Morrison, A.; Ding, C.; Mukherjee, R.; Spinale, FG. Treatment with a growth hormone secretagogue in a model of developing heart failure: effects on ventricular and myocyte function. Circulation, 2001, 103, 308-313.
22. Nagaya, N.; Uematsu, M.; Kojima, M.; Ikeda, Y.; Yoshihara, F.; Shimizu, W.; Hosoda, H.; Hirota, Y.; Ishida, H.; Mori, H.; Kangawa, K. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation, 2001, 104,-1435.
23. Chang, L.; Ren, Y.; Liu, X.; Li, W.G.; Yang, J.; Geng, B.; Weintraub, N.L.; Tang, C. Protective effects of ghrelin on ischemia/reperfusion injury in the isolated rat heart. J. Cardiovasc. Pharmaco., 2004, 43, 165-170.
24. Torsello, A.; Bresciani, E.; Rossoni, G.; Avallone, R.; Tullpano, G.; Cocchi, D.; Bulgarelli, I.; Deghenghi, R.; Berti, F.; Locatelli, V. Ghrelin plays a minor role in the physiological control of cardiac function in the rat. Endocrinology, 2003, 144, 1787-1792.
25. Bodart, V.; Febbraio, M.; Demers A.; McNicoll, N.; Pohankova, P.; Perreault, P.; Sejlitz, T.; Escher, E.; Silverstein R.,L.; Lamontagne D.; Ong, H. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ. Res., 2002, 90, 844-849.
26. Pettersson, I.; Muccioli, G.; Granata, R.; Deghenghi, R.; Ghigo, E.; Ohlsson, C.; Isgaard, J. Natural (ghrelin) and synthetic (hexarelin) growth hormone secretagogues stimulate H9c2 cardiomyocyte cell proliferation. J. Endocrinol., 2002, 175, 201-209.
27. Baldanzi, G.; Filigheddu, N.; Cutrupi, S.; Catapano, F.; Bonissoni, S.; Fubini A.; Malan, D.; Baj, G.; Granata, R.; Brolio, F.; Papotti, M.; Surico, N.; Bussolino, F.; Isgaard, J.; Deghenghi, R.; Sinigaglia, F.; Prat, M.; Muccioli, G.; Ghigo, E.; Graziani, A. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through Erk-1/2 and PI 3-kinase/akt. J. Cell. Biol., 2002, 159,-1037.
28. Pang, J.J.; Xu, R.K.; Xu, X.B.; Cao, J.M.; Ni, C.; Zhu, W.L.; Asotra, K.; Chen, M.C.; Chen, C. Hexarelin protects rat cardiomyocytes rom angiotensin II-induced apoptosis in vitro. Am. J. Physiol. Heart. Circ. Physiol., 2004, 286, H1063-1069.
29. Kola, B.; Hubina, E.; Tucci, S.A.; Kirkham, T.C.; Garcia, E.A.; Mitchell, S.E.; Williams, L.M.; Hawley, S.A.; Hardie, D.G.; Grossman, A.B.; Korbonits, M. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effect via AMP-activated protein kinase. J. Biol. Chem., 2005, 280, 25196-25201
30. Garcia, E.A.; Korbonits, M. Ghrelin and cardiovascular health. Curr. Opin. Pharmacol., 2006, 6, 142-147
31. Broglio, F.; Benso, A.; Valetto, M.R.; Gottero, C.; Quaranta, L.; Podio, V.; Arvat, E.; Bobbio, M.; Bisi, G.; Ghigo, E. Growth hormone-independent cardiotropic activities of growth hormone-releasing peptides in normal subjects, in patients with growth hormone deficiency, and in patients with idiopathic or ischemic dilated cardiomyopathy. Endocrinology, 2001, 14, 105-108.
32. Nagaya, N.; Miyatake, K.; Uematsu, M.; Oya, H.; Shimizu, W.; Hosoda, H.; Kojima, M.; Nakanishi, N.; Mori, H.; Kangawa, K. Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure. J. Clin. Endocrinol. Metab., 2001, 86, 5854-5859.
33. Broglio, F.; Guarracino, F.; Benso, A.; Gottero, C.; Prodam, F.; Granata, R.; Avogadri, E.; Muccioli, G.; Deghenghi R.; Ghigo, E. Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery. Eur. J. Pharmacol., 2002, 448, 193-200.
34. Nagaya, N.; Moriya, J.; Yasumura, Y.; Uematsu, M.; Ono, F.; Shimizu, W.; Ueno, K.; Kitakaze, M.; Miyatake, K.; Kangawa, K. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation, 2004, 110, 3674-3679.